恶拉戈利钠(艾拉戈克钠)2024年的价格是多少钱一盒?

The price of elagolix sodium (elagog sodium) in 2024

The price of the mailed version of elagolix sodium (elagog sodium) is affected by many factors and is not stable The details are as follows:

The price of 150mg*28 tablets is about 13,340$ per box;

The price of 200mg*56 tablets is about 13,340$ per box.

Efficacy of elagolix sodium (elagog sodium)

The administration of elagolix sodium (elagog sodium) causes a dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in reduced blood concentrations of the ovarian sex hormones, estradiol and progesterone. Elagolix sodium (elagolix sodium) is an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by competitively binding to the GnRH receptor in the pituitary gland and is indicated for the treatment of moderate to severe pain associated with endometriosis.

Therapeutic Efficacy of Elaris Sodium

Two similar, double-blind, randomized, 6-month Phase 3 trials (Elaris Endometriosis I and II [EM-I and EM-II]) to evaluate two forms of Elaris Sodium - 150 mg once daily (low-dose arm) and 200 mg twice daily (high dose group).

The trial results showed

After three months, a significantly higher proportion of women taking all doses of elagolix sodium (elagolix sodium) met the clinical response criteria for the two primary endpoints compared with women taking placebo. In elagolix sodium (elagolix sodium) EM-I, the proportions of clinical response to dysmenorrhea in the elagolix sodium low-dose and high-dose groups were 46.4% and 75.8%, respectively, compared with 19.6% in the placebo group;

In elagolix sodium (elagolix sodium) EM-II, the corresponding proportions were 43.4% and 72.4%, respectively, while the placebo group was 22.7%. In elagolix EM-I, the proportion of women with a clinical response to nonmenstrual pelvic pain was 50.4% in the low-dose elagolix group and 54.5% in the high-dose elagolix (elagolix) group. In the placebo group, it was 36.5%;

In elagolix sodium (elagolix sodium) EM-II, the corresponding proportions were 49.8% and 57.8%, respectively, while the placebo group was 36.5%. Benefits in dysmenorrhea and nonmenstrual pelvic pain were sustained after 6 months.

Trial Conclusion

Both high-dose and low-dose elagolix sodium (elagolix sodium) can effectively improve dysmenorrhea and non-menstrual pelvic pain in women with endometriosis-related pain within 6 months.

About elagolix

Endometriosis is a common syndrome that causes significant pain, morbidity, disability, and economic loss. It is an effective medication for treating endometriosis symptoms and a relatively safe option.

Elagolix sodium (elagolix sodium) is a GnRH antagonist that inhibits the entire pituitary-gonadal axis. Reduction in estrogen and progesterone levels results in regression of endometrial lesions and improvement in symptoms. Clinical trials have shown that elagolix sodium (elagolix sodium) can effectively treat dysmenorrhea and non-menstrual pain secondary to endometriosis. It is well tolerated and relatively safe to use. Studies lasting up to 12 months have shown that it is continuously effective, reducing menstrual cramps by up to 75% and non-menstrual pain by 50%-60%. Elagolix sodium (elagolix sodium) was found to be effective compared with placebo and alternative treatments.

Recommended hot articles:

References

Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19. PMID: 28525302.